Presenting author

Daniel Gehrlach

3 presentations

• BH-200 (nelivaptan), a vasopressin V1b receptor antagonist, in genetically defined subgroups of MDD: Precision targeting of HPA-axis dysregulation in the OLIVE phase 2 program

  2026 ASCP Annual Meeting

• T25. BH-200 (nelivaptan), a vasopressin V1b receptor antagonist, in genetically defined subgroups of MDD: Precision targeting of HPA-axis dysregulation in the OLIVE phase 2 program

  2026 ASCP Annual Meeting

• MS02.02. Results of the phase 2 OLIVE trial testing the vasopressin 1b antagonist nelivaptan (BH-200) in major depressive disorder

  2026 ECNP Congress